These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22948089)

  • 21. [Neurofilament protein light in multiple sclerosis].
    Zhang Y; Li X; Qiao J
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2745-9. PubMed ID: 18167263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease].
    Hu Y; He S; Wang J
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1377-9. PubMed ID: 11930632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The measurement of phosphorylated tau in human cerebrospinal fluid as a diagnostic marker for Alzheimer's disease].
    Urakami K; Ito N; Arai H; Ishiguro K; Ohno H; Nakashima K
    Seishin Shinkeigaku Zasshi; 2003; 105(4):393-7. PubMed ID: 12806900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
    Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
    Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease].
    Kaiser E; Schönknecht P; Hunt A; Thomann PA; Pantel J; Schröder J
    Z Gerontol Geriatr; 2008 Dec; 41(6):497-501. PubMed ID: 18327693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies against small heat-shock proteins in Alzheimer's disease as a part of natural human immune repertoire or activation of humoral response?
    Papuć E; Krupski W; Kurys-Denis E; Rejdak K
    J Neural Transm (Vienna); 2016 Apr; 123(4):455-61. PubMed ID: 26566902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers.
    Barten DM; Cadelina GW; Hoque N; DeCarr LB; Guss VL; Yang L; Sankaranarayanan S; Wes PD; Flynn ME; Meredith JE; Ahlijanian MK; Albright CF
    J Alzheimers Dis; 2011; 24 Suppl 2():127-41. PubMed ID: 21422517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies against light neurofilaments in multiple sclerosis patients.
    Bartos A; Fialová L; Soukupová J; Kukal J; Malbohan I; Pitha J
    Acta Neurol Scand; 2007 Aug; 116(2):100-7. PubMed ID: 17661795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Axonal damage markers in cerebrospinal fluid are increased in ALS.
    Brettschneider J; Petzold A; Süssmuth SD; Ludolph AC; Tumani H
    Neurology; 2006 Mar; 66(6):852-6. PubMed ID: 16567701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
    J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Negative neurofilament light and tau immunostaining in frontotemporal dementia.
    Sjögren M; Englund E
    Dement Geriatr Cogn Disord; 2004; 17(4):346-9. PubMed ID: 15178951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer's disease with the use of index values.
    Mulder SD; Hack CE; van der Flier WM; Scheltens P; Blankenstein MA; Veerhuis R
    J Alzheimers Dis; 2010; 22(4):1073-9. PubMed ID: 20930309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.
    Bjerke M; Zetterberg H; Edman Å; Blennow K; Wallin A; Andreasson U
    J Alzheimers Dis; 2011; 27(3):665-76. PubMed ID: 21860087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.
    Maddalena A; Papassotiropoulos A; Müller-Tillmanns B; Jung HH; Hegi T; Nitsch RM; Hock C
    Arch Neurol; 2003 Sep; 60(9):1202-6. PubMed ID: 12975284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects.
    Rosenmann H; Meiner Z; Geylis V; Abramsky O; Steinitz M
    Neurosci Lett; 2006 Dec; 410(2):90-3. PubMed ID: 17095156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties.
    Marksteiner J; Pirchl M; Ullrich C; Oberbauer H; Blasko I; Lederer W; Hinterhuber H; Humpel C
    Pharmacology; 2008; 82(3):214-20. PubMed ID: 18810245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.